Literature DB >> 8039762

Hematologic and cytogenetic analyses of 99 cases of de novo myelodysplastic syndromes.

A D'Emilio1, A Montaldi, M Stella, P Celli, N Guercini, L Tremul, F Rodeghiero.   

Abstract

BACKGROUND. The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by peripheral pancytopenia, abnormal bone marrow differentiation and a high risk of leukemic transformation. The role of karyotypic abnormalities in the pathogenesis of MDS is still unclear. In this paper we present the hematologic and cytogenetic findings in 99 patients with de novo MDS. RESULTS AND CONCLUSIONS. Fifty-three cases had chromosomal abnormalities nor complex karyotypes were associated with the morphologic subsets described by the FAB criteria. Nevertheless, the karyotypic profile is prognostically important, as indicated by the fact that patients with complex karyotype abnormalities have very short survival.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8039762

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  1 in total

1.  5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.

Authors:  May Kung Sutherland; Changpu Yu; Martha Anderson; Weiping Zeng; Nico van Rooijen; Eric L Sievers; Iqbal S Grewal; Che-Leung Law
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.